Verge Genomics has pioneered an advanced all-in-human, artificial intelligence powered drug discovery platform to develop better drugs faster for major medical challenges.

Verge Genomics

Verge Genomics is a next-generation biopharmaceutical start-up using systems biology to accelerate development of life-saving treatments for neurodegenerative diseases. Our platform uses patient genomes, gene expression, and epigenomics to identify new therapeutic gene targets, predict effective drugs, and stratify patient subpopulations for increased clinical success. Verge's approach offers a breakthrough opportunity to identify drugs that dramatically improve patient outcomes and fundamentally lower the cost curve of pharmaceutical development.
 
We are looking for extraordinary individuals to join our motivated team in taking on our generation’s biggest healthcare challenges: ALS, Parkinson’s Disease, and Alzheimer's Disease. Our employees are our most important asset; we are a team of founders, excited to learn, roll up our sleeves, and make a real impact.
 
The startup nature of Verge Genomics provides multiple growth opportunities into other areas of the company. As one of the early employees at Verge, your work will have a direct impact on the foundation of a groundbreaking new drug development model. In addition to competitive compensation and benefits, we offer perks like unlimited vacation/sick days, on-site gym access, and free lunch.
 
Verge actively seeks a diverse applicant pool in order to build the strongest possible workforce. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.

Agent Capital

ALS Investment Fund

Basis Set Ventures

OS Fund

Lifeforce Capital

Threshold

WuXi AppTec

Jonathan Downey

BlackRock

Section 32 Alumni Ventures

Merck Global Health Innovation Fund

Tao Capital Partners

Vulcan Capital

Eli Lilly

On Thursday, our Chief Medical Officer, Diego Cadavid, will join other leaders, patients, and regulatory organizations at the TRICALS Masterclass to discuss advances in clinical trial designs. If you're there, don't miss him share his expertise and experience designing innovative #ALS clinical trials. For more information, visit https://bit.ly/49Ei1ev. 

#clinicaltrials #innovation #ALSResearch

Verge Co-founder and CEO Alice Zhang will present at the virtual Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28th, from 10:45 a.m. - 11:15 a.m. EST. If you are attending, watch Alice's presentation to learn more about Verge's innovative strides in transforming drug discovery and development using #AI and human data. https://bit.ly/42LDaBa 

#Investors #Biotechnology #Innovation #EvercoreISIConference2024

Biotech has long recognized the benefits of using digital endpoints in clinical trials. Putting it into practice has been another matter. Our CMO, Diego Cadavid, spoke to BioCentury Inc. about how Verge is paving the way with a digital-first approach in our proof-of-concept study for #ALS, including incorporating digital endpoints that measure mobility, speech and sleep. Read the article here: https://bit.ly/3I0WjFH

#digitalhealth #biotechnology #clinicaltrials


📢 Reminder: Don't miss CEO & co-founder Alice Zhang’s presentation at the J.P. Morgan Healthcare Conference tomorrow! Alice will share how our AI-powered CONVERGE® platform and patient data are accelerating drug discovery and highlight recent company milestones, including the initiation of our cutting-edge proof-of-concept trial for VRG50635, one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform. 

#JPM24 #VergeGenomics #CEOInsights #AI #JPMWeek

We are thrilled to share the continued progress of our lead drug candidate, VRG50635 with the initiation of a cutting-edge proof-of-concept study for the treatment of #ALS. By leveraging our AI-enabled CONVERGE® platform in combination with patient data and our novel study design, we're enabled to more efficiently discover and develop potential drugs for deadly diseases like ALS. Learn more: https://bit.ly/3HbVNEp 

#JPM24 #DrugDevelopment #Innovation #AI

Metric
Company Name	Verge Genomics
Symbol
MSH ID	COM:VERGEGENOMICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	78
Website	vergegenomics.com
LinkedIn	verge-genomics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:VERGEGENOMICS

Verge Genomics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue